Eligibility Criteria

Inclusion Criteria

- patients after first-ever ischemic stroke with a clinical relevant paresis of the upper and lower limb (general clinical muscle testing below level four)
- correlation of clinical symptoms with a brain imaging (CT or MRI)
- able to communicate with the neurological examiner and understand the aim/matter of the study (with or without aphasia)
- start of the first oral application of the study drug between the fourteenth and 60th day after stroke onset
- older than 13 years
- given written informed consent (or two independent witnesses)

Exclusion Criteria

- intracranial or (chronic) subdural hemorrhages
- any additional neurological or psychiatric illnesses
- instable arrythmia
- not controlled or treated arterial hypertension
- ensured cardioembolic event
- anxiolytica, neuroleptica, or alpha-adrenergic antagonists or agonists respectively
- certain anticonvulsiva or antihypertonica
- manifest hyperthyreosis
- dementia or terminal illnesses
- epilepsy, phaeochromocytoma or glaucoma
- women known to be pregnant or lactating